1 Min Read
April 2 (Reuters) - Strongbridge Biopharma plc:
* FIRST 4 PATIENTS HAVE BEEN DOSED IN LOGICS, A SECOND GLOBAL PHASE 3 STUDY EVALUATING EFFICACY AND SAFETY OF RECORLEV Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.